Verdence Capital Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.18M | Buy |
8,892
+263
| +3% | +$267K | 0.48% | 41 |
|
|
2025
Q4 | $9.27M | Sell |
8,629
-407
| -5% | -$389K | 0.55% | 39 |
|
|
2025
Q3 | $7.47M | Buy |
9,036
+437
| +5% | +$325K | 0.43% | 48 |
|
|
2025
Q2 | $6.7M | Buy |
8,599
+17
| +0.2% | +$13.2K | 0.46% | 49 |
|
|
2025
Q1 | $7.09M | Buy |
8,582
+1,411
| +20% | +$1.17M | 0.54% | 40 |
|
|
2024
Q4 | $5.54M | Buy |
7,171
+17
| +0.2% | +$14.1K | 0.45% | 49 |
|
|
2024
Q3 | $6.34M | Buy |
7,154
+514
| +8% | +$462K | 0.5% | 48 |
|
|
2024
Q2 | $6.01M | Sell |
6,640
-7
| -0.1% | -$5.6K | 0.54% | 43 |
|
|
2024
Q1 | $5.17M | Sell |
6,647
-194
| -3% | -$138K | 0.47% | 50 |
|
|
2023
Q4 | $3.99M | Sell |
6,841
-425
| -6% | -$248K | 0.39% | 59 |
|
|
2023
Q3 | $3.9M | Buy |
7,266
+1,551
| +27% | +$799K | 0.42% | 57 |
|
|
2023
Q2 | $2.68M | Sell |
5,715
-84
| -1% | -$35.2K | 0.31% | 86 |
|
|
2023
Q1 | $1.99M | Buy |
5,799
+67
| +1% | +$22.6K | 0.24% | 112 |
|
|
2022
Q4 | $2.1M | Buy |
5,732
+29
| +0.5% | +$10.3K | 0.26% | 97 |
|
|
2022
Q3 | $1.84M | Buy |
5,703
+66
| +1% | +$20.9K | 0.25% | 105 |
|
|
2022
Q2 | $1.83M | Sell |
5,637
-884
| -14% | -$265K | 0.24% | 112 |
|
|
2022
Q1 | $1.87M | Buy |
6,521
+975
| +18% | +$251K | 0.21% | 120 |
|
|
2021
Q4 | $1.53M | Sell |
5,546
-44
| -0.8% | -$11.2K | 0.18% | 128 |
|
|
2021
Q3 | $1.29M | Buy |
5,590
+89
| +2% | +$22K | 0.17% | 139 |
|
|
2021
Q2 | $1.26M | Sell |
5,501
-116
| -2% | -$23.3K | 0.18% | 132 |
|
|
2021
Q1 | $1.05M | Sell |
5,617
-3,120
| -36% | -$610K | 0.18% | 139 |
|
|
2020
Q4 | $1.48M | Sell |
8,737
-2,996
| -26% | -$447K | 0.28% | 93 |
|
|
2020
Q3 | $1.74M | Sell |
11,733
-394
| -3% | -$61K | 0.4% | 68 |
|
|
2020
Q2 | $1.99M | Buy |
12,127
+6,510
| +116% | +$999K | 0.49% | 55 |
|
|
2020
Q1 | $779K | Sell |
5,617
-5,166
| -48% | -$710K | 0.23% | 116 |
|
|
2019
Q4 | $1.42M | Buy |
10,783
+2,476
| +30% | +$287K | 0.35% | 78 |
|
|
2019
Q3 | $929K | Buy |
8,307
+2,554
| +44% | +$284K | 0.26% | 115 |
|
|
2019
Q2 | $637K | Buy |
5,753
+395
| +7% | +$46.5K | 0.18% | 146 |
|
|
2019
Q1 | $695K | Buy |
5,358
+125
| +2% | +$15.2K | 0.19% | 132 |
|
|
2018
Q4 | $606K | Buy |
5,233
+8
| +0.2% | +$894 | 0.17% | 125 |
|
|
2018
Q3 | $561K | Buy |
5,225
+1,058
| +25% | +$106K | 0.14% | 155 |
|
|
2018
Q2 | $356K | Buy |
4,167
+28
| +0.7% | +$2.3K | 0.09% | 198 |
|
|
2018
Q1 | $320K | Buy |
4,139
+14
| +0.3% | +$1.13K | 0.08% | 217 |
|
|
2017
Q4 | $348K | Buy |
+4,125
| New | +$351K | 0.08% | 189 |
|
Other funds holding LLY
VCM
VPM
Verdence Capital Advisors's LLY Position: Q1 2026 in Review
Verdence Capital Advisors increased its Eli Lilly (LLY) stake by 3% in Q1 2026, buying an estimated $267K and bringing the position to 8,892 shares worth $8.18M. The position accounts for 0.48% of the portfolio, ranked #41.
Verdence Capital Advisors first reported a position in LLY in Q4 2017 and has held it in 34 quarters since. The position peaked at $9.27M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Verdence Capital Advisors held 8,892 shares of Eli Lilly worth $8.18M as of Q1 2026.
- Verdence Capital Advisors bought 263 Eli Lilly shares in Q1 2026, an estimated $267K.
- Eli Lilly made up 0.48% of Verdence Capital Advisors's portfolio in Q1 2026, its #41 holding.
- Verdence Capital Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 34 quarters since.
- Verdence Capital Advisors's Eli Lilly position peaked at $9.27M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.